Phase 3 study · Roche · NCT07416604
Roche's phase 3 NXT007 study for hemophilia A
About 360 people ages 12 and up are planned, and by chance each gets NXT007 or emicizumab (Hemlibra) as preventive shots under the skin. Everyone knows which medicine they get, and after the main period those on emicizumab can switch to NXT007.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Roche's phase 3 NXT007 study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your hematologist.
1. Are you, or the person you care for, 12 or older?
Parents, guardians and caregivers can answer these questions for a teen they care for.2. Is the hemophilia A congenital and severe or moderate, with a factor VIII level of 5IU/dL or lower?
Mild hemophilia A can also qualify when long-lasting factor VIII inhibitors have kept factor VIII under 5IU/dL for at least 12 months.3. Has a factor VIII inhibitor test been done in the 12 months before joining, with the results on record?
Your hematologist or hemophilia treatment center can tell you when the last inhibitor test was done.4. Are there written records of hemophilia treatment and bleeds covering at least the last 6 months?
The listing asks for the details of each treatment used and the number and type of bleeding episodes.5. Would you, or the person you care for, accept plasma or other blood product transfusions in an emergency?
6. Is any surgery planned during the study, other than a minor procedure such as pulling a tooth that is not a molar?
7. Are you, or the person you care for, taking or planning to take a medicine that changes the immune system, such as interferon or rituximab?
The listing allows HIV medicines (antiretroviral therapy) under this rule.The study team also checks for these, which are easier to go over with your hematologist:
- Agreement from people who now treat bleeds only when they happen to switch to regular preventive treatment with the assigned medicine
- A history of irregular heart rhythms that start in the lower heart chambers, or risk factors such as structural or coronary heart disease
- An abnormal heart tracing (ECG) the study doctor considers significant, such as some types of heart block, or a past heart attack
- An allergy or sensitivity to the study medicines or their ingredients that rules out joining, in the study doctor's opinion
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- Center for Inherited Blood DisordersOrange, California · Recruiting
- University of Colorado Hemophilia and Thrombosis CenterAurora, Colorado · Recruiting
- University Of Miami HospitalMiami, Florida · Recruiting
- St Joseph's Children's Hospital of TampaTampa, Florida · Recruiting
- Innovative Hematology, Inc.Indianapolis, Indiana · Recruiting
- University Of Iowa Hospitals And ClinicsIowa City, Iowa · Recruiting
- University of Michigan - 1500 E Medical Center DrAnn Arbor, Michigan · Recruiting
- M Health Fairview - Pediatric Specialty Clinic-DiscoveryMinneapolis, Minnesota · Recruiting
- The University of Texas Health Science Center at San AntonioSan Antonio, Texas · Recruiting
- Washington Center for Bleeding DisordersSeattle, Washington · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07416604.
Questions people ask about Roche's phase 3 NXT007 study
Is Roche's phase 3 NXT007 study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-11-03. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Roche's phase 3 NXT007 study?
The listing names 10 US sites, in California, Colorado, Florida, Indiana, Iowa, Michigan and 3 other states. The full list is in the sites section of this page.
Who can join Roche's phase 3 NXT007 study?
About 360 people ages 12 and up are planned, and by chance each gets NXT007 or emicizumab (Hemlibra) as preventive shots under the skin. The main listed requirements are in the pre-check on this page, starting with: ages 12 and older. Only the study team decides who can join.
How do I contact the Roche's phase 3 NXT007 study team?
The listing names this contact: Roche clinical trials, reference study BO45887, 888-662-6728 (U.S. Only), global-roche-genentech-trials@gene.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Roche. This page restates the public listing in plain words, and nothing here is medical advice; talk with your hematologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07416604, last updated there 2026-11-03. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your hematologist about whether a study is right for you.